Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
暂无分享,去创建一个
A. LaCasce | D. Neuberg | P. Armand | K. Ballen | D. Fisher | E. Jacobsen | Jennifer R. Brown | P. Amrein | L. Werner | E. Attar | E. Hochberg | K. Leahy | T. Takvorian | R. Hasserjian
[1] Ronald Levy,et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. , 2010, Blood.
[2] J. Leonard,et al. Activity of SYK and PLCγ2 Predict Apoptotic Response of Chronic Lymphocytic Leukemia Cells to SRC Tyrosine Kinase Inhibitor Dasatinib. , 2009 .
[3] Martin C. Müller,et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. , 2008, Blood.
[4] A. Sanil,et al. Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects , 2009, Journal of clinical pharmacology.
[5] G. Altavilla,et al. Dasatinib induces a response in chronic lymphocytic leukemia. , 2009, Blood.
[6] N. K. Williams,et al. Crystal Structures of the Lyn Protein Tyrosine Kinase Domain in Its Apo- and Inhibitor-bound State* , 2009, Journal of Biological Chemistry.
[7] M. Hallek,et al. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. , 2008, Blood.
[8] S. Romano,et al. The effect of FK506 on transforming growth factor β signaling and apoptosis in chronic lymphocytic leukemia B cells , 2008, Haematologica.
[9] G. Roos,et al. The GNAS1 T393C polymorphism and lack of clinical prognostic value in chronic lymphocytic leukemia. , 2008, Leukemia research.
[10] Jennifer R. Brown,et al. Pseudohyperkalemia in chronic lymphocytic leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Luca Laurenti,et al. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. , 2008, Blood.
[12] A. Kater,et al. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. , 2008, Blood.
[13] G. Leone,et al. Constitutive Activation of the Protein Tyrosine Kinase Syk in Chronic Lymphocytic Leukemia B-Cells. , 2007 .
[14] R. Küppers,et al. The GNAS1 T393C Polymorphism Is Associated with Disease Progression and Survival in Chronic Lymphocytic Leukemia , 2006, Clinical Cancer Research.
[15] P. Sherrington,et al. B-cell receptor translocation to lipid rafts and associated signaling differ between prognostically important subgroups of chronic lymphocytic leukemia. , 2005, Cancer research.
[16] K. Do,et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Ting,et al. CATERPILLER 16.2 (CLR16.2), a Novel NBD/LRR Family Member That Negatively Regulates T Cell Function* , 2005, Journal of Biological Chemistry.
[18] A. Brunati,et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. , 2005, The Journal of clinical investigation.
[19] M. Hilgarth,et al. Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2 , 2005, Leukemia.
[20] F. Lee,et al. The SRC/ABL Inhibitor BMS-354825 Overcomes Resistance to Imatinib Mesylate in Chronic Myelogenous Leukemia Cells through Multiple Mechanisms. , 2004 .
[21] Ping Chen,et al. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.
[22] J. Byrd,et al. Frequency and type of serious infections in fludarabine‐refractory B‐cell chronic lymphocytic leukemia and small lymphocytic lymphoma , 2002, Cancer.
[23] H. Kantarjian,et al. Results of First Salvage Therapy for Patients Refractory to a Fludarabine Regimen in Chronic Lymphocytic Leukemia , 2002, Leukemia & lymphoma.
[24] M Chilosi,et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. , 2001, Blood.
[25] C Stratowa,et al. CDNA microarray gene expression analysis of B‐cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking , 2001, International journal of cancer.
[26] B. Cheson,et al. Clinical trials referral resource. Clinical trials with perillyl alcohol. , 1997, Oncology.
[27] M. Grever,et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.
[28] R. Geha,et al. Signal transduction via CD40 involves activation of lyn kinase and phosphatidylinositol-3-kinase, and phosphorylation of phospholipase C gamma 2 , 1994, The Journal of experimental medicine.
[29] N. Chiorazzi,et al. mechanisms of disease Chronic Lymphocytic Leukemia , 2010 .
[30] S. Gibson,et al. Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. , 2008, British journal of haematology.
[31] M. Merville,et al. NF- kappa B2/p100 induces Bcl-2 expression. , 2003, Leukemia.